Conversely, other studies showed that P-gp, MRP2, multidrug resistance-associated protein 1 (MRP1), and ABC subfamily G member 2 (ABCG2) are key resistance factors that control the pharmacokinetics and pharmacodynamics of sorafenib in HCC [52]. The gene discussed is ABCC2; the disease is hepatocellular carcinoma.